{"id":"https://openalex.org/W2767770516","doi":"https://doi.org/10.1097/yic.0000000000000203","title":"A phase II study to evaluate the pharmacokinetics, safety, and tolerability of Risperidone ISM multiple intramuscular injections once every 4 weeks in patients with schizophrenia","display_name":"A phase II study to evaluate the pharmacokinetics, safety, and tolerability of Risperidone ISM multiple intramuscular injections once every 4 weeks in patients with schizophrenia","publication_year":2017,"publication_date":"2017-11-06","ids":{"openalex":"https://openalex.org/W2767770516","doi":"https://doi.org/10.1097/yic.0000000000000203","mag":"2767770516","pmid":"https://pubmed.ncbi.nlm.nih.gov/29112001"},"language":"en","primary_location":{"id":"doi:10.1097/yic.0000000000000203","doi":"https://doi.org/10.1097/yic.0000000000000203","is_oa":false,"landing_page_url":"https://doi.org/10.1097/yic.0000000000000203","pdf_url":null,"source":{"id":"https://openalex.org/S149156103","display_name":"International Clinical Psychopharmacology","issn_l":"0268-1315","issn":["0268-1315","1473-5857"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310318547","host_organization_name":"Wolters Kluwer","host_organization_lineage":["https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Clinical Psychopharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5012684643","display_name":"Lourdes Anta","orcid":"https://orcid.org/0000-0001-5981-1850","observed_orcids":["https://orcid.org/0000-0001-5981-1850"]},"institutions":[{"id":"https://openalex.org/I4210089961","display_name":"Laboratorios Farmace\u00faticos Rovi (Spain)","ror":"https://ror.org/00fc1yz57","country_code":"ES","type":"company","lineage":["https://openalex.org/I4210089961"]}],"countries":["ES"],"is_corresponding":true,"raw_author_name":"Lourdes A. Carabias","raw_affiliation_strings":["Laboratorios Farmac\u00e9uticos ROVI, Madrid, Spain","to Lourdes A. Carabias, PhD, Laboratorios Farmac\u00e9uticos ROVI, S.A. Calle Alfonso G\u00f3mez, 45A, 28037 Madrid, Spain Tel: +34 917 617 587; fax: +34 913 047 881; e-mail: [email\u00a0protected]"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Laboratorios Farmac\u00e9uticos ROVI, Madrid, Spain","institution_ids":["https://openalex.org/I4210089961"]},{"raw_affiliation_string":"to Lourdes A. Carabias, PhD, Laboratorios Farmac\u00e9uticos ROVI, S.A. Calle Alfonso G\u00f3mez, 45A, 28037 Madrid, Spain Tel: +34 917 617 587; fax: +34 913 047 881; e-mail: [email\u00a0protected]","institution_ids":["https://openalex.org/I4210089961"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054084707","display_name":"Jordi Llaud\u00f3","orcid":"https://orcid.org/0000-0001-7573-3100","observed_orcids":["https://orcid.org/0000-0001-7573-3100"]},"institutions":[{"id":"https://openalex.org/I4210089961","display_name":"Laboratorios Farmace\u00faticos Rovi (Spain)","ror":"https://ror.org/00fc1yz57","country_code":"ES","type":"company","lineage":["https://openalex.org/I4210089961"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Jordi Llaud\u00f3","raw_affiliation_strings":["Laboratorios Farmac\u00e9uticos ROVI, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Laboratorios Farmac\u00e9uticos ROVI, Madrid, Spain","institution_ids":["https://openalex.org/I4210089961"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000848927","display_name":"Ignacio Ayani","orcid":"https://orcid.org/0000-0001-7654-3763","observed_orcids":["https://orcid.org/0000-0001-7654-3763"]},"institutions":[{"id":"https://openalex.org/I4210089961","display_name":"Laboratorios Farmace\u00faticos Rovi (Spain)","ror":"https://ror.org/00fc1yz57","country_code":"ES","type":"company","lineage":["https://openalex.org/I4210089961"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Ignacio Ayani","raw_affiliation_strings":["Laboratorios Farmac\u00e9uticos ROVI, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Laboratorios Farmac\u00e9uticos ROVI, Madrid, Spain","institution_ids":["https://openalex.org/I4210089961"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014324002","display_name":"Javier Mart\u00ednez","orcid":"https://orcid.org/0000-0001-6314-4480","observed_orcids":["https://orcid.org/0000-0001-6314-4480"]},"institutions":[{"id":"https://openalex.org/I4210089961","display_name":"Laboratorios Farmace\u00faticos Rovi (Spain)","ror":"https://ror.org/00fc1yz57","country_code":"ES","type":"company","lineage":["https://openalex.org/I4210089961"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Javier Mart\u00ednez","raw_affiliation_strings":["Laboratorios Farmac\u00e9uticos ROVI, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Laboratorios Farmac\u00e9uticos ROVI, Madrid, Spain","institution_ids":["https://openalex.org/I4210089961"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014722269","display_name":"Robert E. Litman","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Robert E. Litman","raw_affiliation_strings":["CBH Health, LLC, Rockville, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CBH Health, LLC, Rockville, Maryland, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5067167326","display_name":"Ib\u00f3n Gutierro","orcid":"https://orcid.org/0000-0002-7533-9194","observed_orcids":["https://orcid.org/0000-0002-7533-9194"]},"institutions":[{"id":"https://openalex.org/I4210089961","display_name":"Laboratorios Farmace\u00faticos Rovi (Spain)","ror":"https://ror.org/00fc1yz57","country_code":"ES","type":"company","lineage":["https://openalex.org/I4210089961"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Ib\u00f3n Gutierro","raw_affiliation_strings":["Laboratorios Farmac\u00e9uticos ROVI, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Laboratorios Farmac\u00e9uticos ROVI, Madrid, Spain","institution_ids":["https://openalex.org/I4210089961"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5012684643"],"corresponding_institution_ids":["https://openalex.org/I4210089961"],"apc_list":null,"apc_paid":null,"fwci":0.6174,"has_fulltext":false,"cited_by_count":24,"citation_normalized_percentile":{"value":0.67625922,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":98},"biblio":{"volume":"33","issue":"2","first_page":"79","last_page":"87"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T14126","display_name":"Intramuscular injections and effects","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2711","display_name":"Emergency Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/long-acting-injectable-antipsychotics","display_name":"long-acting injectable antipsychotics","score":0.9570000171661377},{"id":"https://openalex.org/keywords/schizophrenia","display_name":"schizophrenia","score":0.8230000138282776},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8970000147819519},{"id":"https://openalex.org/keywords/intramuscular-injection","display_name":"intramuscular injection","score":0.7789999842643738},{"id":"https://openalex.org/keywords/monthly-dosing","display_name":"monthly dosing","score":0.7070000171661377},{"id":"https://openalex.org/keywords/hyperprolactinemia","display_name":"hyperprolactinemia","score":0.8379999995231628},{"id":"https://openalex.org/keywords/dystonia","display_name":"dystonia","score":0.7960000038146973},{"id":"https://openalex.org/keywords/injection-site-pain","display_name":"injection site pain","score":0.7900000214576721},{"id":"https://openalex.org/keywords/treatment-emergent-adverse-events","display_name":"treatment-emergent adverse events","score":0.8050000071525574},{"id":"https://openalex.org/keywords/sustained-release","display_name":"sustained drug release","score":0.6460000276565552}],"concepts":[{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.7730502486228943},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7492547631263733},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.6302101016044617},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6186922192573547},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.6150652766227722},{"id":"https://openalex.org/C22979827","wikidata":"https://www.wikidata.org/wiki/Q5137311","display_name":"Cmax","level":3,"score":0.6144344210624695},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5837030410766602},{"id":"https://openalex.org/C2776291583","wikidata":"https://www.wikidata.org/wiki/Q432083","display_name":"Intramuscular injection","level":2,"score":0.5070559978485107},{"id":"https://openalex.org/C2780057945","wikidata":"https://www.wikidata.org/wiki/Q412443","display_name":"Risperidone","level":3,"score":0.4707736670970917},{"id":"https://openalex.org/C2779329155","wikidata":"https://www.wikidata.org/wiki/Q130243","display_name":"Deltoid muscle","level":2,"score":0.4140552282333374},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3061855733394623},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.26307570934295654},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.2144453227519989},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000075662","descriptor_name":"Injection Site Reaction","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":true},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003692","descriptor_name":"Delayed-Action Preparations","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004421","descriptor_name":"Dystonia","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D004421","descriptor_name":"Dystonia","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006966","descriptor_name":"Hyperprolactinemia","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D006966","descriptor_name":"Hyperprolactinemia","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":true},{"descriptor_ui":"D007273","descriptor_name":"Injections, Intramuscular","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010146","descriptor_name":"Pain","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D010146","descriptor_name":"Pain","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D011569","descriptor_name":"Psychiatric Status Rating Scales","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012559","descriptor_name":"Schizophrenia","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":true},{"descriptor_ui":"D012559","descriptor_name":"Schizophrenia","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D016903","descriptor_name":"Drug Monitoring","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true},{"descriptor_ui":"D017063","descriptor_name":"Outcome Assessment, Health Care","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018967","descriptor_name":"Risperidone","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D018967","descriptor_name":"Risperidone","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D018967","descriptor_name":"Risperidone","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1097/yic.0000000000000203","doi":"https://doi.org/10.1097/yic.0000000000000203","is_oa":false,"landing_page_url":"https://doi.org/10.1097/yic.0000000000000203","pdf_url":null,"source":{"id":"https://openalex.org/S149156103","display_name":"International Clinical Psychopharmacology","issn_l":"0268-1315","issn":["0268-1315","1473-5857"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310318547","host_organization_name":"Wolters Kluwer","host_organization_lineage":["https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Clinical Psychopharmacology","raw_type":"journal-article"},{"id":"pmid:29112001","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/29112001","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International clinical psychopharmacology","raw_type":"Clinical Trial, Phase II"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320335152","display_name":"Agencia de Innovaci\u00f3n y Desarrollo de Andaluc\u00eda","ror":"https://ror.org/02yp53r73"},{"id":"https://openalex.org/F4320337372","display_name":"U.S. National Library of Medicine","ror":"https://ror.org/0060t0j89"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":24,"referenced_works":["https://openalex.org/W71712612","https://openalex.org/W131446000","https://openalex.org/W1598068766","https://openalex.org/W1600870989","https://openalex.org/W1953171524","https://openalex.org/W1966949437","https://openalex.org/W1992457778","https://openalex.org/W1999689270","https://openalex.org/W2021861792","https://openalex.org/W2077761247","https://openalex.org/W2104058573","https://openalex.org/W2125138227","https://openalex.org/W2138959943","https://openalex.org/W2140606211","https://openalex.org/W2161570416","https://openalex.org/W2165379748","https://openalex.org/W2167821196","https://openalex.org/W2169197323","https://openalex.org/W2172236423","https://openalex.org/W2200305834","https://openalex.org/W2219812044","https://openalex.org/W2284531888","https://openalex.org/W2464467657","https://openalex.org/W2527103551"],"related_works":["https://openalex.org/W2352123895","https://openalex.org/W2464467657","https://openalex.org/W2288181136","https://openalex.org/W4294123877","https://openalex.org/W4408038509","https://openalex.org/W4407191421","https://openalex.org/W3217388410","https://openalex.org/W1972852190","https://openalex.org/W124451037","https://openalex.org/W4403128038"],"abstract_inverted_index":{"This":[0],"study":[1,53,122,155],"characterized":[2],"the":[3,33,42,59,108,113,121,176,188],"pharmacokinetics,":[4],"safety,":[5],"and":[6,84,107,128,165,182,196,202],"tolerability":[7],"of":[8,29,52,58,71],"Risperidone":[9,170],"ISM,":[10],"a":[11,184],"new":[12],"long-acting":[13],"intramuscular":[14,27,194],"formulation,":[15],"for":[16],"monthly":[17],"administration":[18,181],"without":[19],"oral":[20],"supplementation.":[21],"Patients":[22],"with":[23],"schizophrenia":[24],"received":[25,47],"multiple":[26,193],"injections":[28,195],"75":[30],"mg":[31],"in":[32,91],"gluteal":[34,92],"or":[35,93,132],"deltoid":[36,94],"muscle":[37],"at":[38,48,141],"28-day":[39],"intervals.":[40],"Of":[41],"70":[43],"randomized":[44],"patients,":[45],"67":[46],"least":[49,142],"one":[50,143],"dose":[51],"medication.":[54],"The":[55,157],"mean":[56],"Cmax":[57],"active":[60],"moiety":[61,98],"was":[62,152,197],"achieved":[63,99,172],"24-48":[64],"h":[65,104],"(tmax)":[66],"after":[67,105,179],"each":[68],"administration,":[69],"regardless":[70],"injection":[72,166],"site.":[73],"They":[74],"ranged":[75],"over":[76,192],"four":[77],"consecutive":[78],"doses":[79],"from":[80,175],"39.6":[81],"to":[82,86,154,199],"53.2":[83],"54.1":[85],"61":[87],"ng/ml,":[88],"when":[89],"given":[90],"muscle,":[95],"respectively.":[96],"Active":[97],"therapeutic":[100,173],"levels":[101,109,174],"by":[102],"2":[103],"dose,":[106],"were":[110,123,162],"maintained":[111],"throughout":[112,187],"4-week":[114,189],"dosing":[115,190],"period.":[116],"No":[117],"significant":[118],"changes":[119],"across":[120],"observed":[124],"on":[125],"either":[126],"Positive":[127],"Negative":[129],"Syndrome":[130],"Scale":[131],"Extrapyramidal":[133],"Symptoms":[134],"Scale.":[135],"Overall,":[136],"63":[137],"(94%)":[138],"patients":[139],"experienced":[140],"treatment-emergent":[144],"adverse":[145],"event":[146],"(TEAE).":[147],"One":[148],"serious":[149],"TEAE":[150],"(dystonia)":[151],"related":[153],"treatment.":[156],"most":[158],"frequently":[159],"reported":[160],"TEAEs":[161],"hyperprolactinaemia":[163],"(57.7%)":[164],"site":[167],"pain":[168],"(32.8%).":[169],"ISM":[171],"first":[177],"hours":[178],"drug":[180],"provided":[183],"sustained":[185],"release":[186],"period":[191],"found":[198],"be":[200],"safe":[201],"well":[203],"tolerated.":[204]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":6},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":3}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2017-11-17T00:00:00"}